Trial Profile

Efficacy, safety, and tolerability of gemcitabine and cisplatin in patients with known or potential BRCA or PALB2-mutated pancreas adenocarcinoma.

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 23 Jan 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Veliparib (Primary) ; Cisplatin; Gemcitabine
Indications Adenocarcinoma; Pancreatic ductal carcinoma
Focus Adverse reactions

Most Recent Events

16 Jan 2018 Results published in the Cancer
16 Jun 2014 New trial record
03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com